Article Versions Notes

Adamczyk M, Bartosińska J, Raczkiewicz D, Adamska K, Adamski Z, Czubek M, Kręcisz B, Kłujszo E, Lesiak A, Narbutt J, et al. Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland. Journal of Clinical Medicine. 2023; 12(4):1675. https://doi.org/10.3390/jcm12041675

Adamczyk, Michał, Joanna Bartosińska, Dorota Raczkiewicz, Kinga Adamska, Zygmunt Adamski, Maria Czubek, Beata Kręcisz, Elżbieta Kłujszo, Aleksandra Lesiak, Joanna Narbutt, and et al. 2023. "Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland" Journal of Clinical Medicine 12, no. 4: 1675. https://doi.org/10.3390/jcm12041675

Adamczyk, M., Bartosińska, J., Raczkiewicz, D., Adamska, K., Adamski, Z., Czubek, M., Kręcisz, B., Kłujszo, E., Lesiak, A., Narbutt, J., Noweta, M., Owczarczyk-Saczonek, A., Owczarek, W., Reich, A., Samotij, D., Siekierko, A., Szczęch, J., Walecka, I., Ciechanowicz, P., ... Krasowska, D. (2023). Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland. Journal of Clinical Medicine, 12(4), 1675. https://doi.org/10.3390/jcm12041675